Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Gains from Investment Securities (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Gains from Investment Securities for 16 consecutive years, with $7000.0 as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities fell 99.09% to $7000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27000.0 through Dec 2025, down 98.47% year-over-year, with the annual reading at $27000.0 for FY2025, 98.47% down from the prior year.
  • Gains from Investment Securities hit $7000.0 in Q4 2025 for Ligand Pharmaceuticals, up from -$2.3 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $11.0 million in Q3 2023 to a low of -$15.2 million in Q4 2023.
  • Historically, Gains from Investment Securities has averaged $489944.4 across 5 years, with a median of $760500.0 in 2022.
  • Biggest five-year swings in Gains from Investment Securities: soared 3931.11% in 2022 and later crashed 6593.75% in 2024.
  • Year by year, Gains from Investment Securities stood at $6.0 million in 2021, then tumbled by 82.72% to $1.0 million in 2022, then tumbled by 1560.58% to -$15.2 million in 2023, then surged by 105.08% to $771000.0 in 2024, then crashed by 99.09% to $7000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for LGNDZ at $7000.0 in Q4 2025, -$2.3 million in Q3 2025, and $1.5 million in Q2 2025.